Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0.23 | 0.44 | 0.39 | 0.26 | 0.21 | 0.00 | -0.07 |
| Operating profit | $m | -4.2 | -11.7 | |||||
| Net profit | $m | -1.6 | -4.8 | -5.7 | -6.5 | -5.2 | -4.0 | -16.0 |
| EPS reported | $ | -60.27 | -724.9 | |||||
| Operating cashflow per share | $ | -23.53 | -192.2 | |||||
| Capex per share | $ | 0.09 | 3.77 | |||||
| FCF per share | $ | -23.62 | -195.9 | |||||
| Free cash flow | $m | -3.82 | -4.57 | |||||
| Net debt | $m | -3.09 | -8.46 | |||||
| Book value equity | $m | 16.0 | - | |||||
| Book value per share | $ | 86.99 | - | |||||
| Number of shares | m | 0.18 | 0.02 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.10 | 0.03 | |||||
| P/S LTM | x | 0.00 | -16.56 | |||||
| P/FCF LTM | x | -0.43 | -0.24 | |||||
| EV/EBITDA LTM | x | 0.35 | 0.85 | |||||
| EV/Sales LTM | x | 0.00 | 111.59 | |||||
| Earnings Yield LTM | % | -243.79% | -26856.6% | |||||
| FCF Yield | % | -232.71% | -417.95% | |||||
| Quality | ||||||||
| ROE | % | -25.01% | -161.01% | |||||
| ROIC | % | -21.35% | -72.45% | |||||
| Operating margin | % | 0.00% | 17754.5% | |||||
| Gross margin | % | 0.00% | 263.64% | |||||
| FCF/Sales | % | - | 6919.8% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.85 | -10.72 | |||||
| Net Debt/EBITDA | x | 0.83 | 0.83 | |||||
| EBIT/Net interest | x | -37.11 | -24.93 | |||||
| Net debt/market cap | % | - | -774.02% | |||||
| Net debt/Equity | x | -0.19 | - | |||||
| Gross debt/equity | x | 0.06 | - | |||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Nexentis Technologies Inc. (NXTS)
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free